Transdermal Delivery of Vaccines and Therapeutic Proteins - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Transdermal Delivery of Vaccines and Therapeutic Proteins
The author reviews advances in technology that may soon allow transdermal delivery of two of the fastest growing drug classes on the pharmaceutical market. This article is part of a special Drug Delivery issue.

Pharmaceutical Technology
pp. s14-s20

Transdermal delivery of vaccines

Figure 1: Human epidermal Langerhans cells (stained red) are randomly distributed in the epidermis. Their long dendrites ensure detection of foreign invaders. (FIGURE 1 IS REPRINTED BY PERMISSION FROM NICOLAS AND GUY (REF. 2))
Within the epidermis and the dermis, the skin provides immunological protection to the body. The skin houses specialized cells in both the epidermis (Langerhans Cells, LC) and the dermis (dermal dendritic cells, dDC) (8, 9); these cells are an important component of the immune system and are not found anywhere else in the body. Collectively, these specialized cells act as sentinels, probing their surroundings for signs of immunological threats. They are able to process microbial antigens and ultimately migrate into lymphatic capillaries to lymph nodes initiating an immune response that may be both faster and stronger than that generated in response to the same amount of antigen administered via intramuscular injection. Although LCs account for only 2% of cells in the epidermis, they are relatively large, and their long dendrites stretch across the epidermis to form a tight network that effectively captures particulate- or macromolecule-challengers (see Figure 1).

Dermal dendritic cells play a similar role in the dermis. Upon capture of antigen, both the LCs and the dDCs are directed to the secondary lymph nodes via draining lymphatic capillaries to initiate an immune response (5). An excellent review on the mechanism of intradermal immunization is reported by Nicolas and Guy (2).

The potential for leveraging this specialized system to achieve an enhanced immune response via intradermal vaccine delivery has been recognized for decades. In a 1932 publication, Tuft et al. described a human clinical trial that demonstrated the potential of intradermal delivery to provide an enhanced antibody response to typhoid vaccine. The trial showed that an antibody response, on par with those measured following intramuscular (IM) or subcutaneous (SC) delivery, required only one-seventh as much antigen when delivered intradermally (10).

Since that time, many others have explored and developed the potential benefits associated with intradermal delivery of vaccines. Of particular interest is a 2004 study where researchers studied the efficacy of influenza vaccine administered intradermally. Results showed that an immune response equivalent with or superior to that observed for IM administration can be achieved with intradermal delivery using just one-fifth the amount of vaccine (11). This dose-sparing potential is particularly appealing to the World Health Organization (WHO) and vaccine manufacturers as governments contemplate how to handle perpetual vaccine shortages and to provide adequate civilian protection against a pandemic flu (8).

A 2009 report published by WHO provides a summary of human intradermal vaccination trials that have been conducted (8). Results are categorized by data that demonstrate intradermal delivery studies providing dose superiority, dose equivalence, or dose inferiority when compared with conventional administration routes. A summary of key clinical trials is also provided elsewhere (2).

Figure 2: Comparison of Anti-HBs Ag Titer following intramuscular or intradermal administration of comparable doses in hairless guinea pigs. GMT is group mean titer.
A graphical example of the dose-sparing potential associated with intradermal vaccine delivery is provided below. Figure 2 shows the results of a prime/boost immunogenicity study conducted in hairless guinea pigs (HGPs). Hepatitis B surface antigen (HBsAg) was coated onto the tips of 1300 polymeric microneedles contained on a patch approximately 1 cm in diameter and inserted approximately 150 m into the skin so as to deliver the vaccine to the epidermis and upper dermis. The microneedle patches were held in place with an adhesive ring for 15 min. before being removed. Anti-HBsAg titers were determined at 4 weeks (boost), 8 weeks (boost), and 12 weeks after primary immunization. An equal amount of antigen was delivered to a second group of HGPs via IM injection, who were dosed following the same schedule (12).

Devices and components designed to help make ID delivery of vaccines a reality are an exciting continuation of the potential posited by Tuft in the early 1930s.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here